{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:51:06Z","timestamp":1793508666051,"version":"4.5.0"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The discovery of the PD-1 receptor and its ligand PD-L1 revolutionized our understanding of immune regulation and, together with that of CTLA-4, allowed the development of immune checkpoint blockade, now a cornerstone of cancer therapy. Early models emphasized a simplistic view in which PD-L1 expression by tumor cells directly inhibited cytotoxic T lymphocytes through PD-1 engagement. However, recent findings reveal that this pathway is far more complex, involving multilayered regulation of PD-L1 expression, extensive post-translational modifications, and a broad spectrum of interacting partners. In addition to tumor cells, multiple immune and stromal populations, including dendritic cells, macrophages, T cells, and endothelial cells, express PD-L1 and\u00a0critically shape anti-tumor immunity and therapeutic responses. Moreover, PD-L1 exerts intrinsic, non-immune functions within tumor cells, including regulation of proliferation, apoptosis resistance, and metabolic adaptation. PD-1 itself, long viewed as a T-cell-restricted inhibitory receptor, is now recognized as functionally relevant on additional cell types such as natural killer cells, myeloid\u00a0cells, and even tumor cells, further diversifying its role in immune regulation and tumor biology. Together, these insights challenge the classical dogma and call for a refined view of the PD-1\/PD-L1 axis that accounts for its\u00a0cellular heterogeneity, molecular complexity, and bidirectional signalling. Incorporating this knowledge into clinical practice will be essential to improve\u00a0patient stratification, overcome therapeutic resistance, and design innovative combination strategies to fully exploit the potential of immune checkpoint blockade.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1708873","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:33:24Z","timestamp":1764830004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Unlocking the mystery of the PD-1\/PD-L1 axis: beyond the checkpoint hype"],"prefix":"10.3389","volume":"16","author":[{"given":"Pierre-Hubert","family":"Desimpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Florent","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"J Van den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1994.1562","article-title":"Structure and chromosomal localization of the human PD-1 gene (PDCD1)","volume":"23","author":"Shinohara","year":"1994","journal-title":"Genomics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.3493","article-title":"Activation-induced expression of human programmed death-1 gene in T-lymphocytes","volume":"232","author":"Vibhakar","year":"1997","journal-title":"Exp Cell Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061602","article-title":"NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment","volume":"8","author":"Huang","year":"2013","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/07357900801941852","article-title":"TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells","volume":"26","author":"Qian","year":"2008","journal-title":"Cancer Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01337","article-title":"Recent findings in the regulation of programmed death ligand 1 expression","volume":"10","author":"Shen","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours","volume":"3","author":"Yao","year":"2019","journal-title":"Nat BioMed Eng"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/acs.langmuir.4c04441","article-title":"Palmitoylation of PD-L1 regulates its membrane orientation and immune evasion","volume":"41","author":"Zhang","year":"2025","journal-title":"Langmuir"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade4186","article-title":"PD-L1 methylation restricts PD-L1\/PD-1 interactions to control cancer immune surveillance","volume":"9","author":"Huang","year":"2023","journal-title":"Sci Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq4722","article-title":"Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs","volume":"8","author":"Wang","year":"2022","journal-title":"Sci Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"168500","DOI":"10.1016\/j.jmb.2024.168500","article-title":"Deciphering cholesterol\u2019s role in PD-L2 stability: A distinct regulatory mechanism from PD-L1","volume":"436","author":"Zhang","year":"2024","journal-title":"J Mol Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2013Resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of checkMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010066","article-title":"HDAC inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1188926","article-title":"New insights into the therapeutic potentials of statins in cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/OP-24-00583","article-title":"Concomitant statin use and survival in patients with cancer on immune checkpoint inhibitors: A meta-analysis","volume":"21","author":"Liao","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.12.008","article-title":"Statin use with immune checkpoint inhibitors and survival in nonsmall cell lung cancer","volume":"26","author":"Marrone","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-022-09385-8","article-title":"A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study","volume":"22","author":"Takada","year":"2022","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1439231","article-title":"Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7\u20131 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 binds to B7\u20131 only in cis on the same cell surface","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202777","article-title":"Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression","volume":"191","author":"Haile","year":"2013","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205085120","article-title":"Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity","volume":"120","author":"Zhang","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.celrep.2018.06.054","article-title":"Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Cell Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41590-021-01125-7","article-title":"PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity","volume":"23","author":"Sugiura","year":"2022","journal-title":"Nat Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1172\/JCI120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","first-page":"101420","DOI":"10.1016\/j.xcrm.2024.101420","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16015","article-title":"Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis","volume":"111","author":"Dong","year":"2003","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003976","article-title":"B7-h1 expressed by activated CD8 T cells is essential for their survival","volume":"187","author":"Pulko","year":"2011","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B74","doi-asserted-by":"publisher","first-page":"103785","DOI":"10.1016\/j.isci.2022.103785","article-title":"PD-L1(+)CD8(+) T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance","volume":"25","author":"Zheng","year":"2022","journal-title":"iScience"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/713774061","article-title":"Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells","volume":"9","author":"Eppihimer","year":"2002","journal-title":"Microcirculation"},{"key":"B77","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0897","article-title":"Tumor endothelial cell-mediated antigen-specific T-cell suppression via the PD-1\/PD-L1 pathway","volume":"18","author":"Taguchi","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41467-022-29930-0","article-title":"PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration","volume":"13","author":"Piao","year":"2022","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0633","article-title":"Lymphatic PD-L1 expression restricts tumor-specific CD8(+) T-cell responses","volume":"81","author":"Cousin","year":"2021","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-427013","article-title":"Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells","volume":"120","author":"Tewalt","year":"2012","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.19","article-title":"Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases","volume":"23","author":"Thorn","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313075","article-title":"Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway","volume":"66","author":"Wang","year":"2017","journal-title":"Gut"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03531-2","article-title":"PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer","volume":"72","author":"Kawasaki","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B94","doi-asserted-by":"publisher","first-page":"100532","DOI":"10.1016\/j.jtocrr.2023.100532","article-title":"Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00710-9","article-title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer","volume":"34","author":"Emancipator","year":"2021","journal-title":"Mod Pathol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2238896","article-title":"Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: A systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"106628","DOI":"10.1016\/j.intimp.2020.106628","article-title":"Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors","volume":"85","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20191041","article-title":"PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling","volume":"39","author":"Gao","year":"2019","journal-title":"Biosci Rep"},{"key":"B105","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports Malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.075","article-title":"PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity","volume":"20","author":"Gato-Canas","year":"2017","journal-title":"Cell Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e01039","article-title":"Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy","volume":"4","author":"Wu","year":"2018","journal-title":"Heliyon"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.773","article-title":"Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes","volume":"8","author":"Nishimura","year":"1996","journal-title":"Int Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"Int Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.11.7372","article-title":"Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes","volume":"175","author":"Keir","year":"2005","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3133","article-title":"Targeting glycosylated PD-1 induces potent antitumor immunity","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep"},{"key":"B123","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","article-title":"Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection","volume":"40","author":"Crawford","year":"2014","journal-title":"Immunity"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade6256","article-title":"Transmembrane domain-driven PD-1 dimers mediate T cell inhibition","volume":"9","author":"Philips","year":"2024","journal-title":"Sci Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41467-021-22965-9","article-title":"PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B129","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signal"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201100165","article-title":"PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells","volume":"3","author":"Karwacz","year":"2011","journal-title":"EMBO Mol Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-9","article-title":"Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1\/PD-L1 immunotherapy","volume":"5","author":"Bevins","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J Virol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B138","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123757","article-title":"The evolving knowledge on T and NK cells in classic hodgkin lymphoma: insights into novel subsets populating the immune microenvironment","volume":"12","author":"Ferrarini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1557030","DOI":"10.1080\/2162402X.2018.1557030","article-title":"PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression","volume":"8","author":"Mariotti","year":"2019","journal-title":"Oncoimmunology"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0185-0","article-title":"Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells","volume":"19","author":"Quatrini","year":"2018","journal-title":"Nat Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.044","article-title":"Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells","volume":"147","author":"Quatrini","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj3286","article-title":"When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer","volume":"8","author":"Hasim","year":"2022","journal-title":"Sci Adv"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-203141","article-title":"PD-1 on dendritic cells impedes innate immunity against bacterial infection","volume":"113","author":"Yao","year":"2009","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809422106","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2106","article-title":"Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection","volume":"16","author":"Said","year":"2010","journal-title":"Nat Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100274","article-title":"Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer","volume":"186","author":"Krempski","year":"2011","journal-title":"J Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0813443","article-title":"Negative role of inducible PD-1 on survival of activated dendritic cells","volume":"95","author":"Park","year":"2014","journal-title":"J Leukoc Biol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0748","article-title":"PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-kappaB","volume":"76","author":"Karyampudi","year":"2016","journal-title":"Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e1085146","DOI":"10.1080\/2162402X.2015.1085146","article-title":"PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity","volume":"5","author":"Lim","year":"2016","journal-title":"Oncoimmunology"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.214","article-title":"The PD-1\/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia","volume":"31","author":"Qorraj","year":"2017","journal-title":"Leukemia"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1518","article-title":"Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases","volume":"7","author":"Dhupkar","year":"2018","journal-title":"Cancer Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","article-title":"Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment","volume":"41","author":"Klement","year":"2023","journal-title":"Cancer Cell"},{"key":"B163","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/0008-5472.CAN-09-1592","article-title":"Modulation of T-cell activation by Malignant melanoma initiating cells","volume":"70","author":"Schatton","year":"2010","journal-title":"Cancer Res"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2148","article-title":"PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFkappaB pathway","volume":"7","author":"Mirzaei","year":"2021","journal-title":"Sci Adv"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0761","article-title":"Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ Chemoresistant lung cancer cells","volume":"29","author":"Rotolo","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921445117","article-title":"Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004032","article-title":"In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies","volume":"10","author":"Ierano","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804453105","article-title":"Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2","volume":"105","author":"Lazar-Molnar","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J Exp Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022089","article-title":"B7DC\/PDL2 promotes tumor immunity by a PD-1-independent mechanism","volume":"197","author":"Liu","year":"2003","journal-title":"J Exp Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7:CD28 family and friends: Unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06026-3","article-title":"Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance","volume":"617","author":"Park","year":"2023","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:33:26Z","timestamp":1764830006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":176,"alternative-id":["10.3389\/fimmu.2025.1708873"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1708873","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"article-number":"1708873"}}